Hargreaves, Richard

Lack of Efficacy of the Substance P (Neurokinin1 Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder

Keller, M., Montgomery, S., Ball, W., Morrison, M., Snavely, D., Liu, G., Hargreaves, R., Hietala, J., Lines, C., Beebe, K., et al. (2006) · Biological Psychiatry

Treatment of Major DepressionTryptophan and brain disorders

Cited by 286

Structure-dependent Impairment of Intracellular Apolipoprotein E4 Trafficking and Its Detrimental Effects Are Rescued by Small-molecule Structure Correctors

Brodbeck, J., McGuire, J., Liu, Z., Meyer-Franke, A., Balestra, M. E., Jeong, D.-E., Pleiss, M., McComas, C., Hess, F., Witter, D., et al. (2011) · Journal of Biological Chemistry

Alzheimer's disease research and treatmentsCellular transport and secretion

Cited by 113

Development of aprepitant, the first neurokinin‐1 receptor antagonist for the prevention of chemotherapy‐induced nausea and vomiting

Hargreaves, R., Ferreira, J. C. A., Hughes, D., Brands, J., Hale, J., Mattson, B., & Mills, S. (2011) · Annals of the New York Academy of Sciences

Nausea and vomiting managementPharmacogenetics and Drug Metabolism

Cited by 102

Reducing Abuse Liability of GABAA/Benzodiazepine Ligands via Selective Partial Agonist Efficacy at α1 and α2/3 Subtypes

Ator, N. A., Atack, J. R., Hargreaves, R. J., Burns, H. D., & Dawson, G. R. (2010) · The Journal of Pharmacology and Experimental Therapeutics

Neuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on Behavior

Cited by 66

Equivalent Dynamic Human Brain NK1-Receptor Occupancy Following Single-Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging

Van Laere, K., De Hoon, J., Bormans, G., Koole, M., Derdelinckx, I., De Lepeleire, I., Declercq, R., Sanabria Bohorquez, S. M., Hamill, T., Mozley, P. D., et al. (2012) · Clinical Pharmacology & Therapeutics

Nausea and vomiting managementPharmacogenetics and Drug Metabolism

Cited by 46

Benzodiazepine Binding Site Occupancy by the Novel GABAA Receptor Subtype-Selective Drug 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in Rats, Primates, and Humans

Atack, J. R., Wong, D. F., Fryer, T. D., Ryan, C., Sanabria, S., Zhou, Y., Dannals, R. F., Eng, W.-S., Gibson, R. E., Burns, H. D., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics

Neuroscience and Neuropharmacology ResearchPharmacological Receptor Mechanisms and Effects

Cited by 36